Tylosin Global Market Report 2024

The tylosin market size has grown strongly in recent years. It will grow from $0.7 billion in 2023 to $0.74 billion in 2024 at a compound annual growth rate (CAGR) of 5.3%. The growth observed in the historical period can be attributed to factors such as increased livestock production, the utilization of antibiotic growth promoters (AGPs), heightened awareness regarding veterinary health, government regulations and approvals, and a rise in the prevalence of livestock diseases.

The tylosin market size is expected to see strong growth in the next few years. It will grow to $0.93 billion in 2028 at a compound annual growth rate (CAGR) of 5.8%. The projected growth in the forecast period is expected to be driven by factors such as rising global meat consumption, a heightened focus on animal health and welfare, the expansion of livestock farming in emerging markets, regulatory changes including bans on antibiotic growth promoters, and a growing demand for organic and antibiotic-free meat products. Significant trends anticipated for this period encompass increasing demand for antibiotic alternatives, the implementation of stringent regulatory policies, advancements in precision livestock farming technologies, expansion of the organic and antibiotic-free meat market, and the growth of veterinary services and infrastructure.

The upward trend in meat production is anticipated to drive the expansion of the tylosin market in the foreseeable future. Meat production encompasses the processes of raising, slaughtering, and processing animals to obtain meat for human consumption. This increase in meat production is fueled by consumer preferences for nutritious, ethically sourced food products, as well as concerns regarding animal welfare and environmental sustainability. Tylosin, commonly utilized in livestock as an antibiotic to combat bacterial infections such as respiratory diseases and gastrointestinal issues, is also employed as a growth promoter in certain regions. For example, according to the Department for Environmental Food and Rural Affairs, a UK-based governmental department, total meat production in the US reached 4.2 million tonnes in 2022, marking an 18% increase from a decade earlier. Notably, red meat production witnessed a significant surge, particularly in mutton and lamb, experiencing a growth rate of 2.9%. Moreover, home-fed production witnessed a slight uptick from 4,178 to 4,182 between 2020 and 2022. Hence, the escalating demand for healthy livestock is propelling the growth of the tylosin market.

Prominent companies operating in the tylosin market are dedicated to developing innovative solutions such as tulathromycin injection to enhance treatment options for livestock diseases. Tulathromycin injection, a broad-spectrum antibiotic utilized in veterinary medicine, serves to combat respiratory and other infections in livestock. For instance, in May 2022, Merck & Co. Inc., a US-based pharmaceutical company, introduced Tulathromycin injection (Arovyn), available in vials of 50, 100, 250, and 500 ml. This medication is prescribed for the treatment of bovine respiratory disease (BRD), foot rot, and pinkeye in cattle, as well as respiratory disease in swine. Effective against pathogens such as Mannheimia haemolytica, Pasteurella multocida, and Moraxella bovis, tulathromycin offers a cost-effective treatment option for veterinarians and producers. It is essential to note that it should not be administered to female dairy cattle aged 20 months or older, and there's a withdrawal period of 18 days for cattle and five days for swine before slaughter.

In August 2021, Elanco Animal Health Incorporated, a US-based pharmaceutical company, finalized the acquisition of Kindred Biosciences Inc. for $444 million. Through this acquisition, Elanco significantly bolsters its position in the pet health sector, particularly in dermatology, by adding three potential dermatology blockbusters and research and development programs. Kindred Biosciences Inc. is a US-based biopharmaceutical company focused on developing pet therapeutics and macrolides used to treat animal infections.

Major companies operating in the tylosin market are Eli Lilly and Company, Zoetis Inc., Elanco Animal Health Inc., Ceva Santé Animale, Apeloa Pharmaceutical co. ltd, Phibro Animal Health Corporation, Shandong Lukang Pharmaceutical Co. Ltd, Vetoquinol S.A., Norbrook Inc., Qilu Animal Health Products Co. Ltd., Merck & Co. Inc., Hebei Veyong Animal Pharmaceutical, Suanfarma SA, Huvepharma AD, Rochem International Inc, AdvaCare Pharma, Ningxia Tairui Pharmaceutical Co. Ltd., HangZhou Think Chemical Co. Ltd., Vetgen Healthcare Pvt Ltd, Anhui Sinotech Industrial, Pucheng Chia Tai Biochemistry Co Ltd, All Chem Bio Sciences, Nestlife Science Pvt Ltd, Sunvet Pharma Private Ltd, BOC Sciences.

North America was the largest region in the tylosin market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the tylosin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the tylosin market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tylosin, an antibiotic belonging to the macrolide class, is widely employed in veterinary practice to combat various bacterial infections in animals, notably in livestock such as cattle, swine, poultry, and companion animals such as dogs and cats. It plays a pivotal role in veterinary medicine by effectively treating bacterial infections in animals, thereby promoting the health and well-being of both livestock and companion animals.

The primary forms of tylosin available include tylosin tartrate, tylosin phosphate, and others. Tylosin tartrate, a variant of the antibiotic tylosin, finds common usage in veterinary medicine for addressing bacterial infections in livestock. It is utilized in various applications such as animal feed additives, animal drugs, among others, and is distributed through channels including hospital pharmacies, drug stores, retail pharmacies, and online providers.

The tylosin research report is one of a series of new reports that provides tylosin market statistics, including the tylosin industry's global market size, regional shares, competitors with a tylosin market share, detailed tylosin market segments, market trends and opportunities, and any further data you may need to thrive in the tylosin industry. This tylosin market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The tylosin market consists of sales of oral powders, premixes, water-soluble powders, and injectable solutions. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.